Advancing IgAN Care: Exploring the Next Wave of Treatments

Panelists discuss how IgA nephropathy presents in patients, often remaining asymptomatic until significant progression occurs, and explore the various subtypes that exhibit distinct clinical features.

Panelists discuss the progressive nature of immunoglobulin AIgA nephropathy (IgAN) and identify key factors that may accelerate its progression toward end-stage renal disease (ESRD).

Panelists discuss the immune system dysregulation underlying IgA nephropathy and highlight how this mechanism differs from those seen in other glomerular diseases.

Panelists discuss potential biomarkers and clinical indicators that can aid in predicting disease outcomes for individual patients with IgA nephropathy.

Panelists discuss the importance of screening and monitoring family members of individuals with IgA nephropathy, noting that up to 15% of cases are familial and outlining recommendations for the frequency of such assessments.

Panelists discuss how IgA nephropathy affects patients’ quality of life, addressing both the physical symptoms and the emotional challenges associated with the condition.

Panelists discuss how misdiagnosis and delayed diagnosis of IgA nephropathy occur, highlighting the primary barriers to timely detection and strategies to overcome these challenges.

Panelists discuss how clinicians can differentiate IgA nephropathy from other glomerular diseases, such as lupus nephritis and membranous nephropathy, that may present with similar clinical features.

Panelists discuss how clinicians determine the significance of proteinuria in assessing patients for potential IgA nephropathy (IgAN), including the levels and patterns that prompt further investigation and the specific diagnostic red flags that may suggest IgAN over other kidney disorders.

Panelists discuss how clinicians determine the significance of proteinuria in assessing patients for potential IgA nephropathy (IgAN), including the levels and patterns that prompt further investigation and the specific diagnostic red flags that may suggest IgAN over other kidney disorders.

Panelists discuss how integrating additional biomarkers with proteinuria measurements can enhance the diagnostic accuracy for IgA nephropathy.

Panelists discuss how the primary treatment goals for patients with IgA nephropathy evolve based on the stage of the disease, emphasizing the importance of tailoring strategies to individual patient needs.

Panelists discuss how the reduction of proteinuria is integral to the broader treatment goals for IgA nephropathy, highlighting evidence that supports its role in preventing long-term kidney damage.

Panelists discuss how clinicians can effectively shift treatment strategies for IgA nephropathy from merely managing symptoms to actively targeting the root causes of the disease.